Etoposide, epirubicin and carboplatin in hormone-refractory prostate cancer

International Urology and Nephrology

Volumn 28, Issue 1, 1996, Pages 79-85

  Fuse, H ^a   Muraishi, Y ^a   Fujishiro, Y ^a   Katayama, T ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; CARBOPLATIN; CHLORMADINONE ACETATE; EPIRUBICIN; ESTRAMUSTINE PHOSPHATE; ESTROGEN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; HUMAN; MALE; NAUSEA; PROSTATE CANCER; TREATMENT OUTCOME;

EID: 0029973698     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02550142     Document Type: Article

References (21)

1. Eagan, R., Hahn, R., Myers, R.: Adriamycin (NSC-123127) versus 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC-26271) in the treatment of metastatic prostate cancer. Cancer Treat. Rep., 60, 115 (1976).
2. Elomaa, I., Kellokumpu-Lehtinen, P., Rannikko, S., Alfthan, O.: Hormone-resistant metastatic prostate cancer. Comparisons between estramustine phosphate and low-dose epirubicin treatments. Eur. Urol., 19, 12 (1991).
3. Fergusson, J. F., Hendry, W. F.: Pituitary irradiation in advanced carcinoma of the prostate: Analysis of 100 cases. Br. J. Urol., 43, 514 (1971).
4. Huggins, C., Hodges, C. V.: Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res., 1, 293 (1941).
5. Japanese Urological Association & Japanese Pathological Society: General Rules for Clinical and Pathological Studies on Prostatic Cancer. Kanehara, Tokyo 1985.
6. Johnson, D. E., Scott, W. W., Gibbons, R. P., Prout, G. R., Schmidt, J. D., Chu, T. M., Gaeta, J., Saroff, J., Murphy, G. P : National randomized study of chemotherapeutic agents in advanced prostatic carcinoma: A progress report. Cancer Treat. Rep., 61, 317 (1977).
7. Jones, W. G., Fosså, S. D., Bono, A. V., Klijn, J. G. M., De Pauw, M., Sylvester, R.: European Organization for Research and Treatment of Cancer (EORTC) phase II study of low-dose weekly epirubicin in metastatic prostate cancer. Cancer Treat. Rep., 71, 1317 (1987).
8. Klein, L. A.: Prostatic carcinoma. N. Engl. J. Med., 300, 824 (1979).
9. Kontturi, M., Sotarauta, M., Tammela, T., Lukkarinen, O , Romppainen, M.-L., Gröhn, P.: Sequentially alternating hormone chemotherapy with high-dose medroxy-progesterone acetate and low-dose epirubicin for the treatment of hormone-resistant metastatic prostatic cancer Eur. Urol., 15, 43 (1988).
10. Lerner, H , Malloy, T.: Hydroxyurea in stage D carcinoma of prostate. Urology, 10, 35 (1977).
11. Merrin, C., Beckley, S., Treatment of estrogen-resistant stage D carcinoma of the prostate with cis diamminedichloroplatinum. Urology, 13, 267 (1979).
12. Scher, H. I., Sternberg, C. N., Heston, W. D. W., Watson, R C., Niedzwiecki, D., Smart, T., Hollander, P., Yagoda, A., The Community Cancer Oncology Program Investigators: Etoposide in prostatic cancer. Experimental studies and phase II trial in patients with bidimensionally measurable disease. Cancer Chemother. Pharmacol., 18, 24 (1986).
13. Schmidt, J. D., Johnson, D. E., Scott, W. W., Gibbons, R. P., Prout, G. R., Murphy, G. P.: The National Prostatic Cancer Project: Chemotherapy of advanced prostatic cancer. Urology, 7, 602 (1976).
14. Scott, W. W., Johnson, D. E., Schmidt, J. E., Gibbons, R. P., Prout, G. R., Joiner, J. R., Saroff, J., Murphy, G P.: Chemotherapy of advanced prostatic carcinoma with cyclophosphamide or 5-fluorouracil: Results of first national randomized study. J. Urol., 114, 909 (1975).
15. Tejda, F., Eisenberger, M., Broder, L., Cohen, M., Simon, R.: 5-Fluorouracil versus CCNU in the treatment of metastatic prostatic cancer. Cancer Treat. Rep., 61, 1589 (1977).
16. Torti, F. M., Carter, S. K.: The chemotherapy of prostatic adenocarcinoma. Ann. Intern. Med., 92, 681 (1980).
17. Trump, D. L., Loprinzi, C. L.: Phase II trial of etoposide in advanced prostate cancer. Cancer Treat. Rep., 68, 1195 (1984).
18. Trump, D. L., Marsh, J. C., Kvols, L K., Citrin, D., Davis, T. E., Hahn, R. G., Vogl, S. E.: A phase II trial of carboplatin (NSC 241240) in advanced prostate cancer, refractory to hormonal therapy. An Eastern Cooperative Oncology Group pilot study. Invest. New Drugs, 8 (Suppl.), 91 (1990).
19. Walther, P. J., Williams, S. D., Troner, M., Greco, F. A., Birch, R., Einhorn, L. H.: The Southeastern Cancer Study Group. Cancer Treat. Rep., 70, 771 (1986).
20. Wilke, H., Preusser, P., Fink, U., Gunzer, U., Meyer, H.-J., Meyer, J., Siewert, J. R., Achterrath, W., Lenaz, L., Knipp, H., Schmoll, H. J.: Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: A phase II study with etoposide, doxorubicin, and cisplatin. J. Clin. Oncol., 7, 1318 (1989).
21. Yagoda, A., Petrylak, D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer, 71, 1098 (1993).